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Pulmonary gas exchange relies on a rich capillary network,
which, together with alveolar epithelial type I and II cells, form
alveolar septa, the functional units in the lung.Alveolar capillary
endothelial cells are critical in maintaining alveolar structure,
because disruption of endothelial cell integrity underlies several
lung diseases. Here we show that targeted ablation of lung cap-
illary endothelial cells recapitulates the cellular events involved
in cigarette smoke-induced emphysema, one of the most preva-
lent nonneoplastic lung diseases. Based on phage library screen-
ing on an immortalized lung endothelial cell line, we identified a
lung endothelial cell-binding peptide, which preferentially
homes to lung blood vessels. This peptide fused to a proapopto-
tic motif specifically induced programmed cell death of lung
endothelial cells in vitro as well as targeted apoptosis of the lung
microcirculation in vivo. As early as 4 days following peptide
administration, mice developed air space enlargement associ-
ated with enhanced oxidative stress, influx ofmacrophages, and
up-regulation of ceramide. Given that these are all critical ele-
ments of the corresponding human emphysema caused by ciga-
rette smoke, thesedata provide evidence for a central role for the
alveolar endothelial cells in the maintenance of lung structure
and of endothelial cell apoptosis in the pathogenesis of emphy-
sema-like changes. Thus, our data enable the generation of a
convenientmousemodel of human emphysema. Finally, combi-
natorial screenings on immortalized cells followed by in vivo
targeting establishes an experimental framework for discovery
and validation of additional ligand-directed pharmacodelivery
systems.
The alveolar septum is the critical lung functional unit
involved in gas exchange. This unit is composed by a virtual
cellular syncytium comprised by types I and II epithelial cells
(1), which form the interface between air and blood flowing
within an extensive capillary network (roughly the size of a ten-
nis court) lined by endothelial cells. Disruption of alveolar
integrity occurs in aging and in several lung diseases, particu-
larly in emphysema, a highly prevalent pulmonary disease. Pul-
monary emphysema is a chronic and incurable disease in which
the air spaces distal to the terminal bronchiole are abnormally
and permanently enlarged due to the destruction of their walls
(2), leading to airflow limitation and impaired blood oxygen-
ation. Historically, emphysema has been linked to an excessive
lung inflammation caused by the chronic inhalation of cigarette
smoke and the ensuing protease/anti-protease imbalance (3).
A “vascular hypothesis” for emphysemaoriginated40 years
ago based on the observation of scarcity of pulmonary capillar-
ies in remaining alveolar septa in emphysematous human lungs
(4). More recently, the reports of emphysema caused by vascu-
lar endothelial growth factor (VEGF)5 receptor blockade and
Cre-recombinase-mediated lung VEGF deletion uncovered the
novel role of alveolar cell apoptosis, including endothelial cells,
in the pathogenesis of the disease (5–8). This unique role of
VEGF in lung homeostasis relies on the trophic effect of VEGF
on alveolar endothelial cells (5) and its differentiation-promot-
ing role on type II alveolar cells (9).We have shown that disrup-
tion of VEGF receptor signaling alters the cellular and molecu-
lar maintenance program in the lung and sets up a destructive
cycle involving the mutual interaction of oxidative stress and
apoptosis of alveolar cells (6), under the control of the proapo-
ptotic lipid ceramide (10). These observations were further
confirmed with the report of emphysema in mice in which the
VEGF gene has been deleted by lung expression of CRE recom-
binase (8) and our finding of emphysema in mice treated with
the combination of VEGF-R1 and -R2 blocked with neutraliz-
ingMF1 andDC101 antibodies, respectively (11). Furthermore,
clinical studies supported several elements of this novel para-
digm, notably that, in comparison with normal lungs, human
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emphysema lungs have decreased expression of VEGF and
VEGF receptors, enhanced alveolar cell apoptosis, and
increased levels of proapoptotic lipid ceramide (10–16).
Despite the growing recognition of alveolar cell apoptosis in
the pathogenesis of emphysema, the specific contributions of
individual alveolar cells (endothelial, epithelial, or myofibro-
blastic cells) in triggering disruption of alveolar integrity and
ultimately governing the process of alveolar cell destruction in
emphysema remains unknown. We previously noted that
endothelial cell apoptosis predominated in the accelerated
emphysema caused by cigarette smoke exposure of mice defi-
cient in themaster antioxidant transcription factor NRF-2 (17).
However, other reports emphasized the potential role of epi-
thelial cell apoptosis in cigarette smoke-induced emphysema
(18). Experimental approaches aimed at identifying the struc-
tural and functional roles of the different types of alveolar cells
in alveolar maintenance are crucial for understanding the
mechanisms involved in lung homeostasis and for designing
studies aimed at therapeutic interventions for a wide range of
lung diseases.
Emphysema is characterized by a progressive decrease in
alveolar gas exchange, possibly as the result of a loss of alveolar
capillaries. The potential link between alveolar cell apoptosis
and disruption of molecular and cellular signaling involved in
alveolar structural maintenance and repair has broader impli-
cations in that cigarette smoke-induced alveolar injury may
share pathogenetic features in common with alveolar enlarge-
ment due to aging (19).
There is growing evidence that endothelial cells have unique
biochemical fingerprints that account for tissue- and/or blood
vessel-specific biochemical heterogeneity of the vascular endo-
thelium (20, 21). Recent proteomic approaches have provided
substantial evidence that such premises apply to lung endothe-
lial cells (22). The introduction of combinatorial approaches
has enabled unbiased probing of cell surfaces for differentially
expressed membrane-associated receptors and their homing
ligands in functional screenings (21, 23–25). Given the pheno-
typic attributes of lung vasculature, we hypothesized that the
expression of unique lung endothelial cell-specific peptide
ligands will serve as molecular tools to interrogate the role of
lung capillary endothelial cells in maintaining in vivo alveolar
integrity.
Here we used ImmortoMouse-derived lung endothelial cells
to screen a phage display random peptide library, since these
immortalized cells retain several important molecular features
corresponding to the tissue of origin (26, 27). These endothelial
cells are part of a panel of tissue-specific microvascular endo-
thelialcell lines fromtheH-2Kb-tsA58mouse(termedImmorto-
Mouse) (27); such endothelial cells harbor a temperature sen-
sitive SV40 large T antigen under the major histocompatibility
complexH-2Kb promoter and are conditionally immortal when
cultured under permissive temperatures (26, 27).
In the present work, we postulated that lung endothelial cells
have unique cell surface molecular characteristics, distinct
from other vascular beds, that allows for selection of specific
peptides using a phage display library. Furthermore, this unique
peptide would permit organ-specific in vivo targeting with a
proapoptotic agent to address whether selective alveolar capil-
lary endothelial cell apoptosis triggers the seminal features seen
in cigarette smoke-induced emphysema. The combination of in
vitro screening and in vivo validation presented here not only
enables one to study the specific role of lung endothelial cell
apoptosis in the pathogenesis of emphysema but also provides
an experimental blueprint to development of a ligand-directed
targeted pharmacology in other systems.
MATERIALS AND METHODS
Animals—Institutional animal care and utilization commit-
tees of the University of Texas M. D. Anderson Cancer Center
and at The Johns Hopkins University approved all animal
experiments. BALB/c and C57Bl6/J mice were purchased from
Jackson Laboratory, and H-2Kb-tsA58 mice were purchased
from Charles River Breeding Laboratories.
Cell Culture and Synthetic Peptides—H-2Kb-tsA58 mouse
microvascular endothelial cell lines derived frombonemarrow,
brain, kidney, lung, and prostate (27) were cultured in 10% fetal
bovine serum (FBS) in Dulbecco’s modified Eagle’s medium
(DMEM) at 33 °C. Cells were cultured at 37 °C for at least 48 h
to induce a quiescent state. The synthetic peptides CGSPG-
WVRC, CGSPGWVRC-GG-D(KLAKLAK)2, and D(KLAK-
LAK)2 were obtained commercially (AnaSpec; San Jose, CA) to
our specifications. In some binding experiments, as indicated, a
synthetic cyclic peptide (sequence CARAC) served as an unre-
lated negative control. For in vivo peptide homing validation,
biotin-conjugated CGSPGWVRC and CARAC were also
obtained.
Cell Surface Binding Assay—We used the BRASIL method
(24) as described. Briefly, for the screening of the phage display
random peptide library for lung endothelial cell binding pep-
tides, 109 transducing units (TU) of CX7C phage library (23)
was first incubatedwith 106 brain endothelial cells in 1% bovine
serum albumin (BSA) in DMEM for 1 h on ice and centrifuged
through organic phase for 10 min at 10,000  g. The upper
aqueous phase was then moved to a new tube with 106 lung
endothelial cells and incubated on ice for 2 h. The phage/cell
admixture was then centrifuged through the organic phase for
10 min at 10,000  g. Eppendorf tubes were frozen at 80 °C
for at least 10 min, and the bottom of the tube containing the
cell pellet was sliced off to a new tube. Cell-bound phage were
recovered by Escherichia coli k91kan bacterial infection for 30
min at room temperature, and phage recovery was determined
from serial dilution on Luria-Bertani (LB) plates containing tet-
racycline (40 g/ml) and kanamycin (100 g/ml). Recovered
phage were amplified in bacterial liquid culture overnight
before purification for the subsequent rounds of selection. For
the phage binding assays, 109 TU of phage were incubated with
2.5–5  105 cells in 1% BSA in DMEM for 2 h on ice and
centrifuged through the organic phase for 10 min at 10,000  g
(24).
Cell Internalization Assay—Lung and prostate endothelial
cells were grown in tissue chamber slides (Lab-Tek II Chamber
Slide System; Nalgene Nunc International Corp., Naperville,
IL), washed twice with phosphate-buffered saline (PBS), incu-
bated with 109 TU of CGSPGWVRC phage or control phage in
1%BSA inDMEMat 37 °C, andwashed five times with PBS and
four times with 150mMNaCl, 20mM glycine, pH 2.3, to remove
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cell surface binding phage. Cells were washed with PBS, fixed
with paraformaldehyde in PBS for 15 min, washed with PBS,
permeabilized with 0.2% Triton X-100, washed with PBS, and
blocked with 1% BSA in PBS. Cells were then incubated with a
1:200 dilution of the anti-M13 bacteriophage antibody (Amer-
sham Biosciences) in 1% BSA in PBS at room temperature for
2 h, washed with PBS, and incubated with a 1:200 dilution of a
Cy3-conjugated anti-rabbit secondary antibody in 1% BSA in
PBS for 1 h at room temperature. Finally, cells were washed
with PBS, fixed with 4% PFA in PBS, mounted, and visualized
under a fluorescence microscope.
In Vitro Cell Viability and Cell Apoptosis Assays—Cells (2 
104 cells/well) were seeded in 96-well plates for 24 h in 10% FBS
in DMEM, incubated with increasing concentrations of the
peptidesCGSPGWVRC-GG-D(KLAKLAK)2 orCGSPGWVRC
and D(KLAKLAK)2 in 80 l of 1% FBS in DMEM for 6 hours at
37 °C. After 6 h, cell viability was measured with a cell prolifer-
ation detection reagent according to the manufacturer’s
instructions (WST-1; Roche Applied Science). All samples
were assayed in triplicate. For the detection of cell apoptosis,
cells were incubated with 100 M CGSPGWVRC-GG-
D(KLAKLAK)2 or CGSPGWVRC and D(KLAKLAK)2 peptides
for 2 h. Cell apoptosis was detected by Annexin-V binding
(ApoAlert; BD Biosciences) and terminal deoxynucleotidyl-
transferase biotin-dUTP nick end labeling (TUNEL) (DeadEnd
fluorometric TUNEL system; Promega, Madison, WI) accord-
ing to the manufacturer’s instructions.
Phage Binding Experiments in Vivo and ex Vivo—Avertin-
anesthetized BALB/c mice (0.015 ml/g) were injected intra-
venously with either 109 TU of CGSPGWVRC-displaying
phage or insertless control fd-tet phage (n  3 mice for each
phage clone). Phage were allowed to circulate for 10 min, and
the animals were perfused through the left ventricle of the heart
with DMEM. The lung and control organs were dissected and
homogenized. Homogenates were washed with ice-cold
DMEMcontaining a protease inhibitormixture (Sigma) and 1%
BSA. Tissue-bound phage were recovered by infecting log
phase k91kan bacteria with the tissue homogenates for 1 h at
room temperature. Serial dilutions of the infected bacteriawere
plated on LB plates containing tetracycline (40 g/ml) and
kanamycin (100g/ml) to determine the recovered phage titer.
Alternatively, anesthetized BALB/cmice were injected intrave-
nously with 1011 TU of CGSPGWVRC-displaying phage or
insertless fd-tet phage (n  3 mice for each phage clone). After
24 h, anesthetizedmicewere perfused through the left ventricle
of the heart with DMEM. Phage were recovered from the tis-
sues as described above. For ex vivo phage binding experiments,
lungs or spleen of a PBS-perfused BALB/c mouse were minced
and digested with collagenase A (Sigma) for 3 h at 37 °C. More
than 50% of the cells in the lung cell suspension were CD31-
positive by flow cytometry (data not shown). The cell suspen-
sion was washed twice with 10% FBS in DMEM and filtered
through a 70-m cell strainer, resulting in single cell suspen-
sion. Lung-derived or spleen-derived cells (106) were incu-
bated with CGSPGWVRC-displaying phage or control phage
(109 TU) for 2 h on ice in 1%FBS inDMEM.The cell/phage ad-
mixtures were then centrifuged through the organic phase, and
cell-bound phage were recovered and titered as described (24).
For in vivo peptide homing validation, anesthetized BALB/c
mice were injected intravenously with 0.2 mol of biotin-con-
jugated CGSPGWVRC or CARAC peptides (n  2 mice for
each peptide-biotin). After 2 h, anesthetized mice were per-
fused through the left ventricle of the heart with 4% paraform-
aldehyde in PBS. Peptide-biotin was detected by streptavidin-
fluorescein (Amersham Biosciences). For blood vessel
localization, tissues were co-stained with an anti-CD31 anti-
body (MEC 13.3) (BD Pharmingen).
Treatment of Mice with CGSPGWVRC-GG-D(KLAKLAK)2—
Adult (3months old)C57Bl6/6Jmice received intraperitoneally
normal saline solution, 240g ofCGSPGWVRC-GG-D(KLAK-
LAK)2 peptide, or 240g of CGSPGWVRC and D(KLAKLAK)2
(separately or a 1:1 mixture as indicated) peptides every other
day. Treatment was terminated 4 days (n  2 mice/treatment
group, treated with CGSPGWVRC-GG-D(KLAKLAK)2 or
D(KLAKLAK)2), 7 days (for ceramide measurements), or 21
days (n  5 mice/treatment group, treated with CGSPG-
WVRC-GG-D(KLAKLAK)2, peptide controls, or saline) after
the first peptide administration.
Morphologic and Morphometric Analysis—Mice were anes-
thetized with halothane (Halocarbon Laboratories; North
Augusta, SC), and lungs were inflated with 0.5% low melting
agarose at a constant pressure of 25 cm of H2O as described (5).
Lungs were then fixed in 10% formalin and paraffin-embedded.
Tissue sections (5 m) were stained with hematoxylin and
eosin. Mean linear intercepts were measured by computer-as-
sisted morphometry with Image Pro Plus (Media Cybernetics,
Silver Spring, MD; utilized for the day 4 experiment) or Meta-
morph software (Universal Imagining, Frederick, MD). Lung
sections were randomly coded, and representative images (15
per lung section) were acquired by an observer masked for the
identity of the lungs, at 20 lens magnification (6).
TUNEL Assay with Alveolar Epithelial and Endothelial Cell
Colocalization—Lung sections (5 m) from the agarose-in-
flated lungs were treated by the fluorescein-FragEL DNA frag-
mentation detection kit (EMD Biosciences, San Diego, CA) for
the detection of apoptotic cells. Co-localization for type II epi-
thelial cells (surfactant protein C; SpC) or alveolar endothelial
cells (CD34) was performed as described (17). Co-localization
of TUNEL within alveolar myofibroblasts was performed with
anti-smooth muscle cell -actin immunofluorescence. In brief,
slides were prepared as described above and incubated with the
mouse monoclonal anti-smooth muscle cell -actin antibody
(Sigma) at a 1:25 dilution and detected with the Immunogenex
(La Jolla, CA) Mouse-on-Mouse kit with Texas Red as the flu-
orochrome. Quantification of TUNEL-positive cells co-ex-
pressing the selective alveolar cell marker was performed in
selected images by an observer masked for the identity of the
experimental groups. Total TUNEL-positive/4,6-diamidino-
2-phenylindole, dihydrochloride (DAPI)-positive cells were
determined using a macro operation run by the Metamorph
imaging system.
Detection of Active Caspase-3—Immunohistochemical stain-
ing of the active caspase-3 was performed with the active
caspase-3-specific antibody (Abcam, Cambridge, MA) on
5-m lung sections, followed by application of DAPI (Molecu-
lar Probes, Inc., Eugene, OR) 1:10,000 from stock in PBS as
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described (13). Quantification of active caspase-3-positive cells
was done on images (n  15 per lung) captured by an observer
masked to the identity of the slides. Specifically, quantifica-
tion was done with the Metamorph software, by measure-
ments of gray color and total intensity of positive staining,
after conversion of the original red-green-blue settings to
monochrome images. Reduction of background inequalities
was done by using an averaging software algorithm, followed
by segmentation of the positive signal and measurements
based on a relative intensity scale in which the background
(with isotype-matched antibody staining) is set to zero and
the most intense immunohistochemical signal is set to 256
(256-gray scale). The results were normalized by the total
number of cells present in the same microscopic field
detected by subsequent image acquisition with the blue filter
for DAPI-positive cells. Western blot analysis was per-
formed for whole lung lysates as described (17). Densitome-
try data were acquired and analyzed by using ImagePro mor-
phometric software as described.
Detection of Ceramide Levels—Paraffin-embedded lung
sections (5 m) were incubated with monoclonal anti-cera-
FIGURE 1. CGSPGWVRC phage binds specifically to lung endothelial cells. a, CGSPGWVRC phage binding to primary mouse lung microvascular endothelial
cells cultured at either 33 or 37 °C detected by the BRASIL method. b, CGSPGWVRC phage binds specifically to lung endothelial cells but not to endothelial cells
derived from control organs (brain, prostate, bone marrow, or kidney). c, CGSPGWVRC phage binding ex vivo to single-cell suspensions prepared from mouse
lungs. CGSPGWVRC phage did not bind to single-cell suspensions prepared from the control organ (spleen). d, mutation of certain residues within CGSPGWVRC
(to alanine) abolishes phage binding to lung endothelial cells. Bone marrow endothelial cells served as the negative control. Mutant residues are color-coded.
e, CGSPGWVRC phage binding to lung endothelial cells is inhibited in a dose-dependent manner by the cognate synthetic peptide. An unrelated cyclic control
peptide did not affect the phage binding. Shown are means  S.E. from triplicate samples. Insertless control phage served as a negative control phage in a– d.
Fd-tet phage values were set to 1 in a– c.
TABLE 1
Lung endothelial cell-binding peptides recovered after three rounds
of selection
Areas of identity are shown in boldface type.





















a Cysteines are omitted. Number of inserts  89.
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mide antibody (MID 15B4, Alexis; Axxora LLC, San Diego,
CA) by using the DAKO Animal Research Kit (DAKO,
Carpinteria, CA) immunohistochemistry protocol. Isotype
control IgG served as a negative control. Quantification of
ceramide expression was performed on coded images as
described for active caspase-3 expression.We also usedmass
spectroscopy to measure ceramide levels, relying on the con-
comitant use of ceramide standards followed by normaliza-
tion per total lipid concentration, as described (10). Briefly,
tissue lipids were extracted by using the Bligh and Dyer
method (28), and the total lipid content was quantified by
measuring the total lipid phosphorus (Pi) as described (29).
Seven major ceramide species as well as three major molec-
ular species of dihydroceramide were detected via positive
multiple reaction monitoring analysis of transitions of the
[M  H] ion, as described (10).
Immunohistochemical Localization of 8-Oxo-7,8-dihydro-
2-deoxyguanosine (8-Oxo-dG)—Immunohistochemical local-
ization of 8-oxo-dG was performed with an anti-8-oxo-dG
monoclonal antibody (Oxis Research, Portland, OR) or with IgG
isotype-matched negative control and detected with the Vector
Mouse-on-Mouse immunodetection kit (6). Quantification and
normalization were performed as described above.
Immunohistochemical Localization of Inflammatory Cells in
the Lungs—Macrophages were identified by the rat anti-mouse
Mac-3 antibody (BD Pharmingen, San Jose, CA). The number
ofMac-3-positive cells in the lung were then normalized by the
total number of DAPI-positive alveolar cells.
FIGURE 2. CGSPGWVRC peptide mediates internalization of ligands into lung endothelial cells and cell apoptosis. a, CGSPGWVRC peptide mediates
phage internalization into lung endothelial cells. CGSPGWVRC phage or control phage were incubated with lung endothelial cells at 37 °C to allow for phage
internalization. Cells were stained with an anti-bacteriophage antibody after removal of the membrane-bound phage. The upper panels show staining of
permeabilized cells revealing the internalized phage. The lower panels show staining of nonpermeabilized cells, demonstrating the successful removal of
phage from the cell surface. Scale bar, 100 m. b, lung endothelial cells were incubated with increasing concentrations (up to 100 M) of proapoptotic peptide
synthesized in conjunction with the targeting CGSPGWVRC peptide (CGSPGWVRC-GG-D(KLAKLAK)2) or negative control peptides (an equimolar mixture of
CGSPGWVRC and D(KLAKLAK)2). Cell viability was determined by optical absorbance using a cell proliferation detection reagent. Shown are means  S.E. from
triplicate wells. c, lung endothelial cells were incubated with 100 M proapoptotic peptide CGSPGWVRC-GG-D(KLAKLAK)2 or negative control peptides
(equimolar mixture of CGSPGWVRC and D(KLAKLAK)2) for 2 h. Induction of cell apoptosis was detected by Annexin-V-fluorescein isothiocyanate (FITC) binding
(top and middle panels) or TUNEL (bottom, yellow arrows).
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Statistical Analysis—For in vitro experiments and in vivo
phage targeting experiments, results are expressed as mean 
S.E., and their statistical significance was determined by Stu-
dent’s t tests. For the in vivo experiments with the targeted
proapoptotic peptide, comparisons among the study groups
were assessed by analysis of variance by using the programSigma-
Stat (SPSS Inc., Chicago, IL), and statistical significance was set
at a p value of less than 0.05. Normally distributed data are
shown as bar graphs with means  S.E., whereas nonnormally
distributed data are shown with box plots in which the boxes
define the 25th and 75th percentiles, with a line at amedian and
error bars defining the 10th and 90th percentile.
RESULTS
Isolation of a Peptide Ligand to Immortalized Lung Endothe-
lial Cells—Weused the BRASIL (biopanning and rapid analysis
of selective interactive ligands) method (24) to screen a CX7C
phage display random peptide library on ImmortoMouse-de-
rived lung endothelial cells (27). After selection, 89 individual
phage clones were sequenced (Table 1). Up to 78.7% of the
clones included the tetrapeptideGWVRmotif, and 25.8%of the
clones displayed a dominant cyclic peptide insert (sequence
CGSPGWVRC). Moreover, the finding that several genetically
distinct phage clones (different codons) encoded the insert
CGSPGWVRC supported the specificity of our overall screen-
ing approach.
Validation of CGSPGWVRCPhage Binding to Lung Endothe-
lial Cells—We performed a comprehensive characterization of
the binding profile of the CGSPGWVRC phage relative to
appropriate controls (Fig. 1). First we evaluated whether tem-
perature (a surrogate for the level of the large T antigen in the
lung endothelial cells) affected the binding of the dominant
CGSPGWVRC phage clone to ImmortoMouse-derived lung
endothelial cells. We performed phage-binding experiments
with CGSPGWVRC phage or insertless control phage (fd-tet)
on lung endothelial cells cultured either at 33 °C (permissive
temperature) or 37 °C (Fig. 1a). We found no significant differ-
ence in CGSPGWVRC phage binding to lung endothelial cells
cultured at either temperature (143  13-fold binding at 33 °C
versus 119  2-fold binding at 37 °C relative to binding of neg-
ative control phage; Student’s t test, p  0.35). These data
allowed us to use proliferating endothelial cells (cultured at
33 °C) for the subsequent experiments. Next, we evaluated the
tissue of origin specificity of CGSPGWVRC phage binding to
the lung endothelial cells. CGSPGWVRC phage or control
phage were incubated with immortal endothelial cells derived
from brain, prostate, bone marrow, kidney, or lung (27). We
observed markedly increased binding of CGSPGWVRC phage
to lung endothelial cells relative to control phage; moreover,
binding of CGSPGWVRC phage to endothelial cells derived
frombrain, prostate, bonemarrow, or kidneywas detected only
at background levels when compared with control phage (Fig.
1b). To rule out the possibility that the observed tissue-specific
binding of CGSPGWVRC phage was related to adaptation to
cell culture conditions, we also tested the CGSPGWVRCphage
binding ex vivo to single-cell suspensions prepared frommouse
lung or a negative control tissue (mouse spleen was used unless
FIGURE 3. Targeting mouse lung vasculature in vivo. a, the ability of the CGSPGWVRC phage to home to mouse lungs was evaluated after intravenous phage
administration into BALB/c mice. Phage were recovered 10 min later from lungs or control tissues after perfusion. Shown are mean  S.E. of TU from three mice
and triplicate plating. b, the ability of the CGSPGWVRC phage to home and internalize to mouse lungs was evaluated 24 h after an intravenous phage
administration into BALB/c mice. Phage were recovered from lungs or control tissues without perfusion. Shown are mean  S.E. of TU from three mice and
triplicate plating. c, CGSPGWVRC phage or control phage were administered intravenously into mice. Mice were perfused 10 min after the phage injections, and
lungs and control organ were recovered. A bacteriophage-specific antibody was used for staining. Scale bar, 100 m for the panels in the top and middle rows
and 20 m for the bottom row. Insertless phage served as a negative control. d, targeting of CGSPGWVRC synthetic peptide to the lung vasculature was
evaluated by intravenous administration of CGSPGWVRC-biotin. After 1 h of circulation, peptide was detected using a streptavidin-fluorescein isothiocyanate
conjugate (yellow) and co-stained with an endothelial marker specific antibody (CD31; red). Vascular co-localization of CGSPGWVRC-biotin is indicated by the
yellow areas in the merged image. No specific homing was observed to a control organ or when a control peptide-biotin was injected into mice.
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otherwise specified). Consistently, we observed strong binding
(118 12-fold) of CGSPGWVRC phage to lung single-cell sus-
pension relative to control phage binding to the same lung sin-
gle-cell suspension; in contrast, no binding or only minimal
binding (1.7  0.1-fold) of CGSPGWVRC phage to spleen sin-
gle-cell suspension was observed when CGSPGWVRC phage
binding was compared with the control phage binding to
spleen-derived single-cell suspension (Fig. 1c). In order to char-
acterize the role of individual amino acid residues in CGSPG-
WVRC peptide binding to lung endothelial cells, we used site-
directedmutagenesis.We generated different alanine-scanning
versions of the displayed peptide by cloning mutant phage
inserts (CGSAGWVRC, CGSPGAVRC, CGSPGWVAC, and
CGSPGAVAC) and comparing binding of each mutant insert
to insertless control phage. Mutation of the tryptophan residue
to alanine abolished phage binding to lung endothelial cells, and
mutation of the arginine residue to alanine reduced the phage
binding to lung endothelial cells by 92%.Mutation of both tryp-
tophan and arginine residues to alanine abolished phage
binding to lung endothelial cells. Although the proline to
alanine mutation decreased phage binding to lung endothe-
lial cells by 61%, binding of CGSAGWVRC peptide-display-
ing phage to lung endothelial cells was still significant rela-
tive to control phage binding to lung endothelial cells (p 
0.001). These results suggest critical roles for the tryptophan
and arginine residues within the ligand insert CGSPG-
WVRC. None of the mutant phage clones showed binding to
a control endothelial cell line derived from bone marrow
(Fig. 1d). Finally, we found that CGSPGWVRC phage bind-
ing to lung endothelial cells is mediated specifically by the
peptide, since phage binding was inhibited by the cognate
synthetic CGSPGWVRC peptide; an unrelated negative con-
FIGURE 4. Induction of morphological changes in mouse lungs after administration of CGSPGWVRC-GG-D(KLAKLAK)2. a, lung sections of mice 4 days
after treatment with CGSPGWVRC-GG-
D
(KLAKLAK)2 peptide or with control peptides (CGSPGWVRC or D(KLAKLAK)2 peptides) were stained with hematoxylin
and eosin. Lung sections from the CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated mice show increased air space enlargement when compared with the lung
sections from the control-treated mice. Scale bar, 400 m. b, quantification of the mean linear intercept (m) in CGSPGWVRC-GG-D(KLAKLAK)2 and control
peptide-treated lungs after 4 days of peptide treatment. CGSPGWVRC-GG-D(KLAKLAK)2 treatment shows a significant increase in the mean linear intercept
values in versus control-treated mice. c, lung sections from mice treated for 21 days with CGSPGWVRC-GG-D(KLAKLAK)2, control peptides (CGSPGWVRC or
D(KLAKLAK)2), or vehicle alone were stained with hematoxylin and eosin. Lung sections from the CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated mice show
increased air space enlargement when compared with the lung sections from the control-treated mice. Scale bar, 200 m. d, the mean linear intercept (m) was
measured from vehicle, CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated, and control peptide (CGSPGWVRC or D(KLAKLAK)2)-treated animals after 21 days of
treatment. CGSPGWVRC-GG-D(KLAKLAK)2 treatment shows a significant increase in mean linear intercept values compared with control peptide-treated mice.
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trol cyclic peptide at the equivalent molar concentrations
had no inhibitory effect (Fig. 1e). Together, these results
show that the peptide CGSPGWVRC is a potent and specific
ligand to lung-derived endothelial cells.
Lung Endothelial Cell Binding Peptides Mediate Cell
Internalization—We next set out to evaluate whether the
ligand CGSPGWVRC peptide would mediate phage internal-
ization into lung endothelial cells. CGSPGWVRC phage or
control phage were incubated with either lung-derived or pros-
tate-derived endothelial cells. Cells were then washed to
remove noninternalized phage, permeabilized, and stained
with an anti-bacteriophage antibody. A Cy3-conjugated sec-
ondary antibody was used to detect the presence and localiza-
tion of phage particles. After 4 h at 37 °C, CGSPGWVRC phage
particles were internalized into lung endothelial cells (Fig. 2a);
only background staining was observed when control phage or
nonpermeabilized cells were used as negative controls. In con-
trast, CGSPGWVRC phage was not internalized into prostate
endothelial cells (data not shown). Internalization detection of
CGSPGWVRCphage is time-dependent (weak at 30min,mod-
erate at 2–4 h, and strong at 8 h; data not shown). These data
suggest that the CGSPGWVRC peptide can mediate the inter-
nalization of ligands such as phage into lung endothelial cells. In
order to evaluate whether internalization of CGSPGWVRC-
directed ligands can also occur outside of the phage context (i.e.
the targeted delivery of pathobiologically relevant peptide), we
generated and tested a synthetic chimeric peptide of the
CGSPGWVRC ligand fused to the D(KLAKLAK)2 proapoptotic
FIGURE 5. CGSPGWVRC-GG-D(KLAKLAK)2 peptide causes lung cell apoptosis after 21 days of treatment. a, identification of apoptotic (detected by TUNEL;
green) endothelial cells (detected by anti-CD34 antibody; red) and type II epithelial cells (detected by anti-SpC antibody; red) in the lungs of CGSPGWVRC-GG-
D(KLAKLAK)2-, control peptide-, and vehicle-treated mice after 21 days of treatment. Shown are merged images, with co-localization of cell-specific markers and
apoptosis: cytoplasmic marker alone (CD34 or SpC) (red cells) (yellow arrows), TUNEL-positive cells in CD34 or SpC-positive cells (yellow arrowheads), and
TUNEL-positive cells without a cytoplasmic positive markers (large orange arrows). Cell nuclei were stained with DAPI (blue) (inset, top right). b, active caspase-3
expression in lung sections of mice 21 days after treatment with CGSPGWVRC-GG-D(KLAKLAK)2, control peptides (CGSPGWVRC and D(KLAKLAK)2), or vehicle
alone. CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated lungs show abundant active caspase-3-positive cells in the alveolar septa in contrast to control-treated
lungs. Isotype control antibody on CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated lungs was used as a negative control for the active caspase-3 staining.
c, quantification of number of alveolar septal cells positive for active caspase-3. d, increased levels of active caspase-3 were detected in the lungs of CGSPG-
WVRC-GG-D(KLAKLAK)2 peptide-treated mice versus control-treated mice by Western blot analysis of lung tissue lysates with an active caspase-3-specific
antibody. e, densitometric quantification of active caspase-3 expression levels obtained in Western blot analysis normalized to actin levels.
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motif, an amphipathic -helix-forming antimicrobial peptide
that disrupts preferentially eukaryotic mitochondrial mem-
branes upon ligand-directed internalization (25, 30–32).
Increasing concentrations of the lung endothelial cell targeted
CGSPGWVRC-GG-D(KLAKLAK)2 peptide or equimolar
amounts of CGSPGWVRCplus D(KLAKLAK)2 were incubated
with lung endothelial cells at 37 °C, and cell viability was
assessed after 6 h. Treatment of lung endothelial cells resulted
in a dose-dependent decrease in cell viability with CGSPG-
WVRC-GG-D(KLAKLAK)2 peptide, whereas the equimolar
combination of CGSPGWVRC plus D(KLAKLAK)2 peptides
did not have any detectable effect on cell viability (Fig. 2b). The
induction of endothelial cell apoptosis by CGSPGWVRC-GG-
D(KLAKLAK)2 was further confirmed by the presence of two
apoptotic markers (Annexin-V binding and TUNEL) (Fig. 2c).
Taken together, these results indicate that the displayed
CGSPGWVRC insert or the corresponding synthetic peptide
can mediate ligand-directed internalization into lung endothe-
lial cells both inside and outside of the phage particle context in
a time- and dose-dependentmanner and that internalization of
the CGSPGWVRC-GG-D(KLAKLAK)2 proapoptotic peptide
induces programmed cell death of the lung endothelial cells
in vitro.
Validation of CGSPGWVRC Homing to Lung Endothelial
Cells in Vivo—Having characterized ligand-directed binding
and internalization in vitro, we assessed the ability of the
CGSPGWVRC phage to target normal mouse lung vasculature
in vivo. Circulation time is an important variant to consider
while conducting in vivo phage targeting experiments, since the
time frame in which phage are allowed to circulate after intra-
venous administration influences their biodistribution. Thus,
experiments were designed toward detection of phage binding
to the vascular endothelium (5–10 min of circulation before
phage recovery) or toward detection of phage that were inter-
nalized by the endothelium or other nonendothelial tissue lay-
ers (circulation 24 h before phage recovery). After intravenous
administration of CGSPGWVRCphage or control phage, hom-
ing was quantified by phage recovery from tissue homogenates
by host bacterial infection after either 10 min or 24 h of circu-
lation. After 10 min of circulation time, the CGSPGWVRC
phage were enriched in lungs compared with either control
organs or control phage (Fig. 3a). Similarly, after 24 h of circu-
lation, the CGSPGWVRC phage were enriched in lungs com-
pared with control organs and the control phage (Fig. 3b).
Homing of CGSPGWVRC phage to lung vasculature was con-
firmed by immunohistochemical staining of phage on tissue
sections. Strong phage staining was observed in lung tissue sec-
tions but not in control tissue sections of mice that received
CGSPGWVRC phage; in contrast, insertless control phage did
not home to lungs above background levels (Fig. 3c).
To confirm that targeting of the CGSPGWVRC peptide to
the lung vasculature occurs outside of the context of the phage,
we administered intravenously soluble CGSPGWVRC peptide
linked to biotin at its carboxyl terminus and detected lung hom-
ing by streptavidin-fluorescein isothiocyanate on processed
histological sections. We observed clear CGSPGWVRC-biotin
labeling of alveolar capillaries (Fig. 3d), similar to the pattern
observed byCD-31 immunofluorescence. Specificitywas deter-
mined by lack of fluorescence in lung capillaries with an unre-
lated peptide or lack of brain capillary signal with the CGSPG-
WVRC-biotin. Of note, there was some evidence of
CGSPGWVRC-biotin labeling in kidneys and liver, which can
be accounted by elimination and excretion of the injected pep-
tide (data not shown), as supported by the studies described
below. These results show that CGSPGWVRC phage and the
corresponding synthetic peptide target lung blood vessels
in vivo.
Targeted CGSPGWVRC-GG-D(KLAKLAK)2 Causes Acute
and Persistent Emphysematous Changes in the Lungs of Treated
FIGURE 6. CGSPGWVRC-GG-D(KLAKLAK)2 treatment leads to decreased lung cell proliferation. a, lung sections from mice treated for 21 days with
CGSPGWVRC-GG-D(KLAKLAK)2 peptide, control peptides (CGSPGWVRC and D(KLAKLAK)2 peptides), or vehicle alone were double-stained with anti-proliferat-
ing cell nuclear antigen (PCNA) antibody, and DAPI. Proliferating cell nuclear antigen- and DAPI-positive cells are indicated (arrowheads). A markedly decreased
number of proliferating cells (quantification in b) is seen in CGSPGWVRC-GG-D(KLAKLAK)2-treated animals in comparison with control animals. b, quantification
of proliferating cell nuclear antigen-positive cells in the lungs from CGSPGWVRC-GG-D(KLAKLAK)2-treated mice shows a decrease in proliferating cell numbers
when compared with lungs from control-treated mice.
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Mice—Because alveolar cell apoptosis has been linked to alve-
olar destructive enlargement, but there is no evidence that spe-
cific endothelial cell death can direct emphysematous alveolar
enlargement, we sought to determine whether administration
of CGSPGWVRC-GG-D(KLAKLAK)2 peptide to mice would
induce morphological changes in the lungs, particularly
emphysema. Mice given CGSPGWVRC-GG-D(KLAKLAK)2
peptide became very lethargic with difficult breathing, which
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improved in the ensuing hours. Mice treated with control pep-
tide or vehicle did not change their normal behavior after
anesthesia.
As assessed by lung morphometry, C57Bl6/6J mice that
received intraperitoneal injections of 240g of CGSPGWVRC-
GG-D(KLAKLAK)2 peptide or control peptides every other day
for a total of either 4 days or 21 days developed emphysema (Fig.
4). Alveolar destruction was already evident after only 4 days
(two doses) of treatment (Fig. 4, a and b), and it became more
prominent at 21 days (10 doses) of treatment with the peptide
CGSPGWVRC-GG-D(KLAKLAK)2 (Fig. 4c). By the end of the
21-day experiment (n 5mice in each group), CGSPGWVRC-
GG-D(KLAKLAK)2-treated lungs exhibited an approximately
20% increase from a mean linear intercept of 59  0.84 m in
CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treatedmice com-
paredwith 49.7 0.9min control-treatedmicewithCGSPG-
WVRC peptide, 49.5  1.0 m for untargeted D(KLAKLAK)2-
treated mice and 49  0.6 m for vehicle-treated lungs (Fig.
4d). Hematoxylin and eosin-stained tissue sections of several
control organs (kidney, heart, liver, and bone marrow) did not
reveal any detectable histological changes in CGSPGWVRC-
GG-D(KLAKLAK)2-treated mice (Fig. S1).
Targeted CGSPGWVRC-GG-D(KLAKLAK)2 Induces both
Lung Cell Apoptosis andDecreased Lung Cell Proliferation—As
shown above, CGSPGWVRC-GG-D(KLAKLAK)2 peptide
treatment led to lung endothelial cell apoptosis in vitro. Given
that peptide treatment with CGSPGWVRC-GG-D(KLAK-
LAK)2 caused alveolar destruction in mice, we determined
whether this destruction was associated with directed apopto-
sis of alveolar endothelial cells. After 4 days of treatment with
CGSPGWVRC-GG-D(KLAKLAK)2 peptide, staining of lung
sections with DAPI and TUNEL showed abundant TUNEL-
positive cells compared with staining of lung sections from
mice receiving control peptides (supplemental Fig. S2a).
TUNEL-positive cells in lung sections were abundant after
21 days of CGSPGWVRC-GG-D(KLAKLAK)2 peptide treat-
ment (Fig. 5a) (CGSPGWVRC-GG-D(KLAKLAK)2  0.0288
TUNEL/DAPI versus peptide  0.0146 TUNEL/DAPI,
p  0.03; Mann-Whitney rank sum test). Alveolar endothelial,
type II, and myofibroblastic cells were equally affected at day 4
(Fig. S2a). A similar proportion of endothelial and type II cell
death was also identified on day 21 after treatment with
CGSPGWVRC-GG-D(KLAKLAK)2 peptide (Fig. 5a), as
detected by staining of the TUNEL-labeled lung sections with
either a CD34-specific antibody (an endothelial cell marker) or
an SpC-specific antibody (a type II alveolar epithelial cell
marker), or smooth muscle cell -actin-antibody (for myofi-
broblasts). The TUNEL findings were also confirmed by immu-
nohistochemical staining for active caspase-3, which revealed
an increased number of apoptotic cells in the alveolar septa of
the CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated mice;
in contrast, lungs from mice treated with control peptide or
vehicle showed much less active caspase-3-positive cells (Fig.
5b). Increased active caspase-3-positive cells in the alveolar
septa of the CGSPGWVRC-GG-D(KLAKLAK)2 peptide-
treatedmicewere evident after only 4 days of treatment (Fig. S2,
b and c). Enhanced activation of caspase-3 in lungs ofmice after
4 days (Fig. S2, b–e) and after 21 days (Fig. 5, c and d) of treat-
ment with CGSPGWVRC-GG-D(KLAKLAK)2 peptide was fur-
ther confirmed by the detection of increased levels of the
19-kDa active caspase-3 peptide in whole-lung lysates byWest-
ern blot analysis. Densitometric assessment of theWestern blot
reaction at day 21 (Figs. 5, d and e, and S3) showed 3.36  0.89
densitometric units of active caspase-3 in lungs of mice receiv-
ing CGSPGWVRC-GG-D(KLAKLAK)2 peptide (n  5) com-
pared with 0.66  0.19 densitometric units in the lungs of mice
receiving control peptide (n  6). In addition to increased apo-
ptosis of alveolar cells, we also detected decreased cell prolifer-
ation in the lungs of mice treated with CGSPGWVRC-GG-
D(KLAKLAK)2 peptide for 21 days when compared with the
lungs of mice treated with vehicle or control peptide (Fig. 6, a
and b). In sum, these data indicate that systemic administration
of CGSPGWVRC-GG-D(KLAKLAK)2 peptide caused apopto-
sis of alveolar cells.
Targeted CGSPGWVRC-GG-D(KLAKLAK)2 Increases Pul-
monary Oxidative Stress—We have shown that oxidative stress
is critically involved in the pathogenesis of experimental ciga-
rette smoke-induced emphysema (17). Furthermore, we dem-
onstrated that emphysema due to VEGF receptor blockade
depends on the mutual interaction between apoptosis and oxi-
dative stress, since either apoptosis blockade or inhibition of
superoxide anion prevents emphysema development (6).
Immunohistochemical detection of 8-oxo-dGwas used to eval-
uate oxidative stress in the lungs of mice receiving CGSPG-
WVRC-GG-D(KLAKLAK)2 for 4 and for 21 days.After 4 days of
treatment, lung sections from CGSPGWVRC-GG-D(KLAK-
LAK)2-treated mice showed increased 8-oxo-dG expression
when compared with the lung sections from the control pep-
tide-treatedmice (Fig. S4). After 21 days of treatmentwith vehi-
cle or control peptides, a small number of alveolar septal cells
showed staining for 8-oxo-dG (355  20 and 346  17 expres-
sion intensity units, respectively), whereas significantly more
FIGURE 7. Levels of 8-oxo-7,8-dihydro-2-deoxyguanosine and ceramide are increased in CGSPGWVRC-GG-D(KLAKLAK)2-treated lungs (21 days of
treatment). a, CGSPGWVRC-GG-D(KLAKLAK)2 peptide induces oxidative damage to mouse lungs, as indicated by increasing 8-oxo-dG expression. Immuno-
histochemical staining of 8-oxo-dG in lung sections from mice treated for 21 days with CGSPGWVRC-GG-D(KLAKLAK)2 peptide, control peptides (CGSPGWVRC
and D(KLAKLAK)2), or vehicle alone. Isotype control antibody on CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated lungs served as a negative control for anti-8-
oxo-dG staining. Lung sections from the CGSPGWVRC-GG-D(KLAKLAK)2-treated mice show elevated 8-oxo-dG expression compared with control-treated mice.
Scale bar (a and c), 25 m. b, quantification of the 8-oxo-dG intensity in the lung tissues from CGSPGWVRC-GG-D(KLAKLAK)2-treated mice. c and d, analysis of
ceramide species by mass spectrometry shows that lungs of mice treated with the CGSPGWVRC-GG-D(KLAKLAK)2 peptide for 7 days have increased levels of
ceramides (c) as well as dihydroceramides, ceramide precursors in the de novo pathway of ceramide synthesis (d), compared with the lungs from control
peptide (CGSPGWVRC or D(KLAKLAK)2)-treated mice. e, CGSPGWVRC-GG-D(KLAKLAK)2 peptide induces elevation of ceramide levels in mouse lungs. Lung
sections from mice after 21 days of treatment with CGSPGWVRC-GG-D(KLAKLAK)2 peptide, control peptides (CGSPGWVRC and D(KLAKLAK)2), or vehicle alone
were subjected to immunohistochemical staining for ceramide. Ceramide staining in CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated lungs show numerous
ceramide-positive alveolar cells, whereas lungs treated with control peptides or vehicle show only sporadic ceramide-positive cells. f, quantification of
ceramide expression detected by immunohistochemistry is described under “Materials and Methods.”
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cells (617  28 expression intensity units; p  0.05) were
stained in CGSPGWVRC-GG-D(KLAKLAK)2-treated lungs
(Fig. 7, a and b). These results show that emphysema and alve-
olar cell apoptosis due to systemic administration of CGSPG-
WVRC-GG-D(KLAKLAK)2 are associated with enhanced oxi-
dative damage to the lungs.
Targeted CGSPGWVRC-GG-D(KLAKLAK)2 Leads to
Increased Lung Ceramide Levels—Ceramide, a second mes-
senger sphingolipid, triggers apoptosis when up-regulated in
conditions associated with cellular stresses, such as during oxi-
dative stress. We have recently shown that (i) ceramide is a
criticalmediator of lung tissue destruction during development
of emphysema due to VEGF receptor blockade, and (ii) cera-
mide levels are increased in lungs of patients with cigarette
smoke-induced emphysema (10). We quantified total lung cera-
mide levels by mass spectroscopic analysis of ceramide and its
immediate precursor in the de novo synthesis pathway, dihydro-
ceramide and by immunohistochemistry with a specific cera-
mide antibody in the lungs of mice receiving vehicle, control
peptide, or CGSPGWVRC-GG-D(KLAKLAK)2 peptide after 7
or 21 days of treatment, respectively. Mass spectroscopic anal-
ysis of ceramide and its immediate precursor, dihydroceram-
ide, showed an early and significant activation of this apoptotic
signaling pathway (from 930.1 pmol/nmol lipid Pi to 1203.6
pmol/nmol lipid Pi (p  0.04) for ceramide (Fig. 7c) and from
12.6 pmol/nmol lipid Pi to 16.8 pmol/nmol lipid Pi (p  0.04)
for dihydroceramide (Fig. 7d)) of ceramide levels in CGSPG-
WVRC-GG-D(KLAKLAK)2-treated lungs in comparison with
control peptide after 7 days of treatment. Ceramide levels in
CGSPGWVRC-GG-D(KLAKLAK)2-treated lungs were sus-
tained after 21 days of treatment, as assessed by immunohisto-
chemistry, which correlates closely with standard biochemical
assays of ceramide in the lung (10) (p  0.05) (Fig. 7, e and f).
Targeted CGSPGWVRC-GG-D(KLAKLAK)2 Increases the
Number of Inflammatory Cells in the Lungs—Influx of inflam-
matory cells, particularly macrophages, is a constant finding in
smokers, and it has been shown tomediate elastin fiber destruc-
tion via production of metalloprotease-12 (33). Rather than a
proximal event in the course of events leading to emphysema,
recent studies have suggested that macrophage influx follows
alveolar lung injury and enhanced oxidative stress. Consistent
with this hypothesis, we detected increased numbers of alveolar
and septal macrophages in CGSPGWVRC-GG-D(KLAK-
LAK)2-treated lungs as compared with control peptide-treated
or vehicle-treated lungs (Fig. S5).
DISCUSSION
In addition to the classical roles of endothelial cells in inflam-
mation and coagulation, there is a clear realization that the
vascular endothelium contributes to organ embryogenesis, dif-
ferentiation, and acquisition of specialized functions. Further-
more, the role of endothelial cells in organ structural integrity,
as initially identified in the retina (34), also pertained to a wide
range of organs within the circulatory (35), nervous (36), and
respiratory (37) systems. Furthermore, disruption of VEGF sig-
naling in lung endothelial cells results in poorly developed lungs
(9, 37). However, since these studies relied on blockade of
VEGF signaling critical for endothelial cell survival, growth,
and differentiation, they also interrupted similar effects of
VEGF on nonendothelial cells, such as neuronal or type II epi-
thelial cells, also known to expressVEGF receptor 2 (38). Devel-
opment of ligand-directed lung endothelial cell targeting based
on the hypothesis of tissue-specific vascular ZIP codes (21–25,
39–44) allowed us to interrogate the specific role of endothelial
cells in lung structural maintenance and the pathological organ
consequences of its disruption. The results presented here indi-
cate that (i) endothelial cell viability plays a central role in lung
maintenance, and (ii) endothelial cell apoptosis suffices to
recreate the pathophysiological processes involved in emphy-
sematous lung destruction.
Recognition of the functional and phenotypic diversity of
endothelial cells has led to a more detailed understanding of
how endothelial cells provide differentiating cues to surround-
ing specialized cells (45). Not only do lung endothelial cells
interact with branching epithelial structures during develop-
ment (46), but there is evidence that pulmonary artery endo-
thelial cells are phenotypic diverse and segregate as large pul-
monary artery and lungmicrovascular endothelial cells (46, 47).
In line with the uniquemolecular signatures of endothelial cells
of multiple vascular beds, we have identified several peptide
ligands that target specific parts of vasculature after intrave-
nous administration from a large combinatorial random pep-
tide library (21, 23, 40–45, 48, 49). In this study,we selected and
isolated a peptide (CGSPGWVRC) that binds to immortalized
lung microvascular endothelial cells (27) in vitro. We tested
CGSPGWVRC phage binding to several different tissue-spe-
cific endothelial cell lines and found the CGSPGWVRC pep-
tide-mediated phage binding to be specific to lung endothelial
cells. This result was consistent with our screening strategy
designed to minimize or eliminate the recovery of ubiquitous
endothelial cell-binding peptides. Tryptophan and arginine
residues appear to play key roles in the motif binding to lung
endothelial cells, since the mutation of either residue abolishes
the ability of the peptide-displaying phage to bind to lung endo-
thelial cells. Although it is conceivable that the Immorto-
Mouse-derived endothelial cells do not express the full comple-
ment of proteins found in vivo, the CGSPGWVRC phage
consistently showed significant binding enrichment to single-
cell suspension freshly prepared from mouse lungs and homed
to lung septa after intravenous administration.
Wehave previously utilized endothelial cell-specific peptides
to deliver pharmacological compounds, such as chemotherapy
drugs (49), viruses carrying toxic genes (50, 51), or a proapopto-
tic peptide aimed at disrupting mitochondrial integrity causing
an organ-specific or tumor-specific endothelial cell ablation
(25, 30–32). CGSPGWVRC peptide-mediated internalization
of phage particles into cultured immortalized lungmicrovascu-
lar endothelial cells enabled internalization of the proapoptotic
moiety D(KLAKLAK)2, which then induced dose-dependent
apoptotic in vitro cell death. We confirmed several of these
processes in vivo, where CGSPGWVRC peptide-displaying
phage was markedly enriched in mouse lungs 24 h after intra-
venous administration, reflecting the biodistribution and
uptake of the targeted phage particles into the cell population.
Of note, the in vitro effects of the internalized CGSPGWVRC
peptide fused to D(KLAKLAK)2 were validated by the patho-
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physiological consequences of in vivo lung endothelial cell abla-
tion. Endothelial cell targeting and apoptosis was supported by
our in vitro and in vivo localization data. These data suggest that
lung endothelial cells were the primary targets of CGSPG-
WVRC-GG-D(KLAKLAK)2, yet a similar amount of endothe-
lial, epithelial, and myofibroblastic cell death was occurring as
early as day 4 after CGSPGWVRC-GG-D(KLAKLAK)2 admin-
istration. These findings are not surprising, since the net loss of
alveolar structures has to involve increased death of all struc-
tural cells with reduced capacity of cell proliferation. Alveolar
cell apoptosis caused by CGSPGWVRC-GG-D(KLAKLAK)2
led to rapid emphysema development, in which alveolar air
space enlargement was detected as early as 4 days of the tar-
geted peptide administration, further evolving during the
3-week course of peptide treatment. Characteristic pathoge-
netic elements present in both human and experimental
emphysema were detected in the targeted mouse lung, partic-
ularly those related to alveolar cell apoptosis, oxidative stress,
and macrophage infiltration, suggesting that lung microvascu-
lar apoptosis precedes (and may even initiate) these processes.
Consistently, alveolar septal cell death also caused up-regula-
tion of ceramide, a secondmessenger lipid present in increased
levels in human emphysema that mediates and amplifies alve-
olar tissue destruction induced by the VEGF receptor blockade
in mice and rats (10).
The finding of experimental emphysema produced by intra-
tracheal instillation of active caspase-3 (33) or ceramide (10, 12)
revealed that alveolar cell apoptosis suffices to produce
destructive alveolar enlargement. Although these interventions
might have affected initially alveolar epithelial cells, profound
endothelial cell apoptosis was observed after ceramide instilla-
tion (10). The increase in ceramide levels in CGSPGWVRC
peptide-treated lungs suggests that endothelial cell stressmight
underlie the enzymatic activation of ceramide synthesis, as
shown after lipopolysaccharide instillation or radiation-in-
duced endothelial cell injury (52, 53). The ensuing destructive
processes and increased concentrations of ceramide (10) pres-
ent in the alveolar septum may also attract macrophages in
response to an excess of apoptotic cells or endothelial cell injury
(54). This increase in alveolar macrophages may enhance lung
destruction via activation of metalloproteases and cathepsins
(7). Finally, in contrast to the self-limited injury present inmost
animal models of emphysema, our endothelial cell-targeted
model displayed marked decreases in alveolar cell proliferation
in vivo. Since the lung endothelial cell peptide does not alter
endothelial cell proliferation in vitro, disruption of alveolar cell
homeostasis in vivodue to endothelial cell targetingmay under-
lie the decrease in cell proliferation. This finding may not only
support a model of emphysema, which may recapitulate the
irreversible process of alveolar destruction and lack of repair
seen in the human disease, but may uncover an important role
for the alveolar endothelial cell in lung repair mechanisms.
In summary, we provide evidence that lung endothelial cells
have unique phenotypic characteristics and that lung endothe-
lial cell-specific peptides can be identified based on these prop-
erties.We show that lung endothelial cell targeting and alveolar
cell apoptotic ablation through a targeted proapoptotic homing
peptide to lung vasculature is possible. We also demonstrate
that endothelial cell targeting with ensuing programmed alve-
olar cell death sets off pathogenetic processes that ultimately
result in emphysematous lung destruction. These results sup-
port the critical structural role of lung endothelial cells inmain-
taining lung septal integrity andmay offer novelmeans to inves-
tigate fundamental pathobiological processes in emphysema
pathogenesis. Other combinatorial screenings in vitro on
immortalized cells in tandem with in vivo validation strategies
may provide an experimental blueprint for development of a
ligand-directed pharmacology.
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